share_log

四環醫藥:自願公告 - 軒竹生物自主研發1類新藥吡羅西尼單藥治療晚期乳腺癌上市申請獲國家藥監局受理

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - THE NDA OF CLASS 1 INNOVATIVE DRUG BIROCICLIB''S MONOTHERAPY, INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARM FOR THE TREATMENT OF ADVANCED BREAST CANCER, WAS ACCEPTED BY NMPA

香港交易所 ·  Oct 16, 2023 18:03
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more